Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2009 4
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence of loss-of-function FTO mutations in lean and obese individuals.
Meyre D, Proulx K, Kawagoe-Takaki H, Vatin V, Gutiérrez-Aguilar R, Lyon D, Ma M, Choquet H, Horber F, Van Hul W, Van Gaal L, Balkau B, Visvikis-Siest S, Pattou F, Farooqi IS, Saudek V, O'Rahilly S, Froguel P, Sedgwick B, Yeo GS. Meyre D, et al. Among authors: kawagoe takaki h. Diabetes. 2010 Jan;59(1):311-8. doi: 10.2337/db09-0703. Epub 2009 Oct 15. Diabetes. 2010. PMID: 19833892 Free PMC article.
Loss-of-function mutation in the dioxygenase-encoding FTO gene causes severe growth retardation and multiple malformations.
Boissel S, Reish O, Proulx K, Kawagoe-Takaki H, Sedgwick B, Yeo GS, Meyre D, Golzio C, Molinari F, Kadhom N, Etchevers HC, Saudek V, Farooqi IS, Froguel P, Lindahl T, O'Rahilly S, Munnich A, Colleaux L. Boissel S, et al. Among authors: kawagoe takaki h. Am J Hum Genet. 2009 Jul;85(1):106-11. doi: 10.1016/j.ajhg.2009.06.002. Epub 2009 Jun 25. Am J Hum Genet. 2009. PMID: 19559399 Free PMC article.
Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H. Satow A, et al. Among authors: kawagoe takaki h. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9. J Pharmacol Exp Ther. 2009. PMID: 19359526
Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.
Suzuki G, Kawagoe-Takaki H, Inoue T, Kimura T, Hikichi H, Murai T, Satow A, Hata M, Maehara S, Ito S, Kawamoto H, Ozaki S, Ohta H. Suzuki G, et al. Among authors: kawagoe takaki h. J Pharmacol Sci. 2009 Jul;110(3):315-25. doi: 10.1254/jphs.09011fp. Epub 2009 Jun 19. J Pharmacol Sci. 2009. PMID: 19542684 Free article.
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H. Suzuki G, et al. Among authors: kawagoe takaki h. J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. doi: 10.1124/jpet.106.116574. Epub 2007 Mar 14. J Pharmacol Exp Ther. 2007. PMID: 17360958